Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

Now Viewing

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on recent phase 3 trial data for B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies in earlier lines of therapy for multiple myeloma (MM) and how this may shape incorporation into clinical practice. The CARTITUDE-4 and KarMMa-3 trials evaluated ciltacabtagene autoleucel and idecabtagene vicleucel, respectively, in heavily pretreated patients who were mostly lenalidomide-refractory, demonstrating significantly improved progression-free survival over standard therapies.

While promising, there are reservations around widely adopting CAR T-cell therapy at first relapse until long-term benefit is proven. However, for high-risk patients relapsing within 1 to 2 years of diagnosis who rapidly exhaust available therapies, earlier CAR T-cell therapy may be preferred over trying additional conventional salvage regimens with marginal benefit. Still, triaging will be necessary given manufacturing constraints on cell therapy availability. Thoughtful patient selection that balances risk, available therapy options, and logistics is advocated.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.